Aster DM Healthcare Limited (NSE:ASTERDM)
India
· Delayed Price · Currency is INR 580.10
-6.80 (-1.16%)
Jun 6, 2025, 12:31 PM IST
Aster DM Healthcare Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
| Revenue | 41,385 | 36,989 | 29,941 | 102,533 | 86,084 | Upgrade
|
| Revenue Growth (YoY) | 11.88% | 23.54% | -70.80% | 19.11% | -0.50% | Upgrade
|
| Cost of Revenue | 17,279 | 17,231 | 14,352 | 65,858 | 57,021 | Upgrade
|
| Gross Profit | 24,105 | 19,759 | 15,588 | 36,674 | 29,063 | Upgrade
|
| Selling, General & Admin | 9,212 | 9,831 | 7,553 | 10,726 | 8,041 | Upgrade
|
| Other Operating Expenses | 7,248 | 4,146 | 3,545 | 11,103 | 10,372 | Upgrade
|
| Operating Expenses | 18,948 | 16,176 | 13,018 | 28,235 | 24,588 | Upgrade
|
| Operating Income | 5,157 | 3,582 | 2,570 | 8,439 | 4,475 | Upgrade
|
| Interest Expense | -1,238 | -1,061 | -851.5 | -2,551 | -2,921 | Upgrade
|
| Interest & Investment Income | - | 47.8 | 48.6 | 48 | 42 | Upgrade
|
| Earnings From Equity Investments | -189.1 | -113.4 | -112.2 | 5.4 | 35.2 | Upgrade
|
| Currency Exchange Gain (Loss) | - | -2.3 | - | -12.6 | -22.9 | Upgrade
|
| Other Non Operating Income (Expenses) | 1,482 | 156 | 296.2 | 429.4 | 438.9 | Upgrade
|
| EBT Excluding Unusual Items | 5,212 | 2,609 | 1,952 | 6,359 | 2,047 | Upgrade
|
| Merger & Restructuring Charges | -501.4 | - | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | - | 2.6 | 3.1 | 9.7 | 3.1 | Upgrade
|
| Pretax Income | 4,711 | 2,612 | 1,955 | 6,369 | 2,051 | Upgrade
|
| Income Tax Expense | 1,344 | 565.1 | 358.7 | 358 | 272.2 | Upgrade
|
| Earnings From Continuing Operations | 3,367 | 2,047 | 1,596 | 6,011 | 1,778 | Upgrade
|
| Earnings From Discontinued Operations | 50,712 | 68.8 | 3,159 | - | - | Upgrade
|
| Net Income to Company | 54,079 | 2,116 | 4,755 | 6,011 | 1,778 | Upgrade
|
| Minority Interest in Earnings | -300.6 | -822.8 | -505.8 | -750.6 | -300.9 | Upgrade
|
| Net Income | 53,778 | 1,293 | 4,249 | 5,260 | 1,477 | Upgrade
|
| Net Income to Common | 53,778 | 1,293 | 4,249 | 5,260 | 1,477 | Upgrade
|
| Net Income Growth | 4059.83% | -69.58% | -19.22% | 256.02% | -46.59% | Upgrade
|
| Shares Outstanding (Basic) | 498 | 498 | 497 | 497 | 497 | Upgrade
|
| Shares Outstanding (Diluted) | 499 | 498 | 498 | 498 | 498 | Upgrade
|
| Shares Change (YoY) | 0.13% | 0.02% | 0.02% | 0.02% | -1.03% | Upgrade
|
| EPS (Basic) | 107.98 | 2.60 | 8.54 | 10.58 | 2.97 | Upgrade
|
| EPS (Diluted) | 107.85 | 2.60 | 8.53 | 10.57 | 2.97 | Upgrade
|
| EPS Growth | 4050.32% | -69.54% | -19.30% | 255.89% | -46.00% | Upgrade
|
| Free Cash Flow | 790.1 | -6,391 | 11,171 | 8,310 | 11,649 | Upgrade
|
| Free Cash Flow Per Share | 1.58 | -12.83 | 22.44 | 16.69 | 23.41 | Upgrade
|
| Dividend Per Share | 5.000 | 2.000 | - | - | - | Upgrade
|
| Dividend Growth | 150.00% | - | - | - | - | Upgrade
|
| Gross Margin | 58.25% | 53.42% | 52.06% | 35.77% | 33.76% | Upgrade
|
| Operating Margin | 12.46% | 9.68% | 8.58% | 8.23% | 5.20% | Upgrade
|
| Profit Margin | 129.95% | 3.50% | 14.19% | 5.13% | 1.72% | Upgrade
|
| Free Cash Flow Margin | 1.91% | -17.28% | 37.31% | 8.11% | 13.53% | Upgrade
|
| EBITDA | 7,704 | 5,330 | 4,101 | 12,110 | 8,071 | Upgrade
|
| EBITDA Margin | 18.62% | 14.41% | 13.70% | 11.81% | 9.38% | Upgrade
|
| D&A For EBITDA | 2,547 | 1,747 | 1,531 | 3,671 | 3,596 | Upgrade
|
| EBIT | 5,157 | 3,582 | 2,570 | 8,439 | 4,475 | Upgrade
|
| EBIT Margin | 12.46% | 9.68% | 8.58% | 8.23% | 5.20% | Upgrade
|
| Effective Tax Rate | 28.52% | 21.64% | 18.35% | 5.62% | 13.28% | Upgrade
|
| Revenue as Reported | 42,867 | 37,238 | 30,310 | 103,039 | 86,584 | Upgrade
|
| Advertising Expenses | - | 1,028 | 781.5 | 1,373 | 789.9 | Upgrade
|
Updated Jan 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.